However, no correlation has been so far demonstrated between the levels of CD8+ tumor infiltrating lymphocytes and sensitivity to immunotherapy in NSCLC patients with uncommon EGFR mutations, which could be warranted in future correlative studies. The gene discussed is CD8A; the disease is neoplasm.